The Real-World Evidence conference USA 2026, the 2nd Annual EVIDENCE 360 RWE Pricing and Market Access Summit USA Edition, is set to be one of the premier events for healthcare professionals in 2026. This summit will serve as a pivotal platform for U.S. healthcare stakeholders to explore how Real-World Evidence (RWE) is reshaping market access, pricing, and reimbursement strategies across the U.S. healthcare system.

Taking place in Philadelphia, USA, from 08–09 June 2026, the event will bring together leaders from pharma, biotech, payers, regulators, health technology assessment (HTA) bodies, and digital health innovators. These experts will dive deep into the evolving role of RWE, discussing the challenges and opportunities that lie ahead for healthcare systems driven by cost-effectiveness and outcomes-based care.

Why Attend the Real-World Evidence Conference USA 2026?

1. Benchmarking with Industry Leaders:
   The Real-World Evidence conference USA 2026 will provide an excellent opportunity to benchmark how major stakeholders like the Institute for Clinical and Economic Review (ICER) and U.S. payers are leveraging RWE in value assessments. Attendees will gain insights into how these organizations are using RWE to shape pricing, market access, and reimbursement decisions, helping to stay ahead in a competitive environment.
2. Clarity on FDA’s Expectations for RWE in Regulatory Submissions:
   As the regulatory landscape evolves, understanding the FDA’s expectations for RWE is essential. The summit will provide clarity on how RWE is becoming a crucial tool for regulatory submissions, helping organizations align their strategies with the latest guidelines and expectations set by the FDA.
3. Strategies for Fit-for-Purpose RWD:
   Whether working in oncology, rare diseases, or digital health, this Real-World Evidence conference 2026 will highlight strategies for building effective RWD approaches across therapeutic areas. Learn how to tailor these strategies to meet specific needs and maximize the value of evidence generated from real-world data.
4. Case Studies on Successful RWE-Driven Access Pathways:
   The summit will feature Real-World Evidence conference 2026 case studies, showcasing successful examples of how RWE has been used to secure reimbursement wins, label expansions, and navigate complex market access pathways. These practical insights will equip you with the knowledge to replicate such success in your organization.
5. Networking with Industry Leaders:
   One of the key highlights of the Real-World Evidence conference USA 2026 is the unparalleled networking opportunity. Meet and engage with leaders in access, HEOR, regulatory affairs, and digital health who are shaping the future of evidence strategies in the U.S. healthcare system.

Access Full Details here at https://veridonglobal.com/upcoming-conferences/2nd-annual-evidence-360-summit-usa-edition/

Key Highlights of the EVIDENCE 360 USA Summit

• The Evolving Role of RWE in U.S. Market Access and Reimbursement
• Payer Expectations for Evidence, Value, and Outcomes
• Real-World Data Integration into HEOR and Regulatory Strategy
• Leveraging Digital Tools, AI, and Decentralized Data Sources
• Case Studies on Successful RWE-Driven Access Pathways

Why the Real-World Evidence Conference USA 2026 is Essential for Your Strategy

1. Benchmarking RWE Use by U.S. Payers and ICER:
   Discover how U.S. payers and ICER are using RWE to inform value assessments and decision-making processes. By attending, you’ll gain actionable knowledge to refine your RWE strategy and better align with payer needs.
2. Understanding FDA’s Stance on RWE:
   Gain critical insights into the FDA’s evolving stance on Real-World Evidence conference 2026 and regulatory submission requirements. Understanding these expectations will be crucial in ensuring compliance and positioning your organization for success.
3. Designing Fit-for-Purpose RWD Strategies Across Therapeutic Areas:
   Learn how to build real-world data (RWD) strategies that are tailored to specific therapeutic areas, ensuring that your evidence generation efforts align with both clinical and regulatory requirements.
4. Insights from RWE-Backed Label Expansions and Reimbursement Wins:
   The summit will provide case studies demonstrating how Real-World Evidence has driven successful label expansions and reimbursement wins, helping attendees learn practical, real-world strategies for advancing their RWE initiatives.
5. Connecting with Industry Pioneers:
   Meet and collaborate with professionals from the world of pharma, biotech, payers, regulators, and more. Establish relationships that will help guide your future strategies in leveraging Real-World Evidence for market access, pricing, and reimbursement success.

Who Should Attend?

• Pharma and Biotech Professionals looking to understand how RWE can impact pricing, market access, and reimbursement.
• Payers and Health Economists seeking to integrate RWE into their decision-making processes for assessing treatment value.
• Regulatory Professionals interested in aligning with FDA’s evolving expectations for RWE.
• Digital Health Innovators exploring how AI and digital tools can improve RWE generation.
• HTA Bodies interested in improving their use of RWE for more informed health technology assessments.

Register here at https://veridonglobal.com/upcoming-conferences/2nd-annual-evidence-360-summit-usa-edition/2nd-annual-evidence-360-usa-registeration/

The 2nd Annual EVIDENCE 360 RWE Pricing and Market Access Summit USA Edition is the Real-World Evidence conference USA 2026 you don’t want to miss. It is an essential gathering for healthcare professionals to understand how Real-World Evidence is revolutionizing the way market access and pricing strategies are developed. This summit offers unique opportunities to gain valuable insights, engage with industry leaders, and gain a competitive edge in 2026.

Join us in Philadelphia, USA, on June 08–09, 2026, and be part of the transformative discussions that will shape the future of Real-World Evidence in healthcare.